IntegraMed America (
Presentation at Oppenheimer Healthcare Conference
December 14, 2011 2:10 p.m. ET
Jay Higham - CEO
Matt [Nuremberg] - Oppenheimer
Welcome to the 22nd Annual Healthcare Conference. I’m Matt [Nuremberg] with the Healthcare Services Team, and I’d like to introduce IntegraMed. We have with us from the company, CEO Jay Higham.
Thank you very much. Thanks to Oppenheimer for inviting us to this conference. We appreciate being here. I’m going to take a few minutes to walk through this slide deck and try to leave some time at the end for people to ask questions.
IntegraMed is a healthcare services company. We were founded in 1985, so we’re very well established in the United States. We operate in two highly fragmented segments of healthcare, the fertility services field and the varicose vein treatment.
On a combined basis, these two verticals represent about a $6 billion market in the United States, and IntegraMed is the largest provider in both those two segments. We have very little national competition. Both of them are very competitive in each local market, but from a national level there’s nobody that’s doing quite what we do.
We do have that national footprint, and we have rapid growth really driven three ways, through patient acquisition; through de novo new clinic openings, where we’re launching new clinics in major markets across the country; and also in strategic acquisitions. And we have a strong track record in all three components of the growth. That’s resulted over the last five years in compound average top line growth approaching 14% and EBITDA just over 14%.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts